JANX Janux Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$16.26

Period return

+1.12 (+7.40%)

Volume

666.6K

2026-07-21O $15.98 H $16.3 L $15.88 C $16.26MA5 $16.09MA20 $15.68MA60 $14.68MA120 $14.34

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.03%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 09.LowBUY2 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 05. 08.LowBUY2 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 05. 08.LowBUY2 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 04. 29.LowBUY3 months ago
Jones Trading: Buy
US analyst rating / recommendation change.
2026. 04. 20.MediumSELL3 months ago
Barclays: Underweight
US analyst rating / recommendation change.
2026. 04. 16.MediumHOLD3 months ago
UBS: Neutral
US analyst rating / recommendation change.
2026. 02. 27.LowBUY5 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $40.56 · 16 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Sector: Healthcare
Industry

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	1,156,140	$16.07M	0.03%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	961,819	$13.27M	0.02%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	471,009	$6.5M	0.01%	—	New position
4	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	116,099	$1.61M	0.00%	—	New position

Janux Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 09.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 05. 08.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 05. 08.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 04. 29.	Jones Trading	—	Maintain	Buy → Buy	—	Jones Trading: Buy
2026. 04. 20.	Barclays	—	Downgrade	Overweight → Underweight	—	Barclays: Overweight → Underweight
2026. 04. 16.	UBS	—	Downgrade	Buy → Neutral	—	UBS: Buy → Neutral